MagGenome Execs Talk Nanoparticle Tech, Indian Cell And Gene Therapy Opportunities

MagGenome Pvt Ltd, an Indian biotech which develops magnetic nanoparticle-based products for therapeutics and molecular diagnostics, is in the early research stage for a nanoparticle-based adjuvant for vaccines. Scrip spoke to founder Sam Santhosh and CEO and chief scientific officer CN Ramchand to gauge the enabling environment being created in India for cell and gene therapy companies, the increasing linkages between novel drug discovery and diagnostics and the promise of nanotech. On the lookout for start-ups to incubate, Santhosh also spoke about bridging the industry-academia gap via the Charotar University of Science and Technology (CHARUSAT).